Bicara Therapeutics Inc. (BCAX) Discusses Ficerafusp Alfa Clinical Data and Less Frequent Dosing in First-Line HPV-Negative Head and Neck Squamous Cell Carcinoma Transcript
Source: SeekingAlpha
2026-02-25 15:38:03 ET
Bicara Therapeutics Inc. (BCAX) Discusses Ficerafusp Alfa Clinical Data and Less Frequent Dosing in First-Line HPV-Negative Head and Neck Squamous Cell Carcinoma February 20, 2026 8:30 AM EST...
Read the full article on Seeking Alpha
For further details see:
Bicara Therapeutics Inc. (BCAX) Discusses Ficerafusp Alfa Clinical Data and Less Frequent Dosing in First-Line HPV-Negative Head and Neck Squamous Cell Carcinoma Transcript
Bicara Therapeutics Inc.
NASDAQ: BCAX
BCAX Trading
-0.16% G/L:
$18.49 Last:
97,262 Volume:
$18.25 Open:
BCAX Latest News
March 04, 2026 08:30:00 am
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
February 26, 2026 04:01:00 pm
Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
February 24, 2026 11:13:06 pm
Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants
February 24, 2026 04:01:00 pm
Bicara Therapeutics Announces Proposed Public Offering of Common Stock
BCAX Stock Data
$817,548,781
24,302,552
0.5%
33
N/A
Biotechnology & Life Sciences
Healthcare
US
Boston
